Trade-Ideas LLC identified

Jazz Pharmaceuticals

(

JAZZ

) as a post-market laggard candidate. In addition to specific proprietary factors, Trade-Ideas identified Jazz Pharmaceuticals as such a stock due to the following factors:

  • JAZZ has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $70.8 million.
  • JAZZ is down 6.1% today from today's close.

EXCLUSIVE OFFER: Get the inside scoop on opportunities in JAZZ with the Ticky from Trade-Ideas. See the FREE profile for JAZZ NOW at Trade-Ideas

More details on JAZZ:

Jazz Pharmaceuticals Public Limited Company, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. JAZZ has a PE ratio of 24. Currently there are 10 analysts that rate Jazz Pharmaceuticals a buy, no analysts rate it a sell, and 2 rate it a hold.

The average volume for Jazz Pharmaceuticals has been 599,900 shares per day over the past 30 days. Jazz has a market cap of $7.7 billion and is part of the health care sector and drugs industry. The stock has a beta of 0.94 and a short float of 3.9% with 2.64 days to cover. Shares are down 13.3% year-to-date as of the close of trading on Tuesday.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

TheStreetRatings.com

Analysis:

TheStreet Quant Ratings

rates Jazz Pharmaceuticals as a

buy

. The company's strengths can be seen in multiple areas, such as its revenue growth, compelling growth in net income, notable return on equity, reasonable valuation levels and expanding profit margins. We feel its strengths outweigh the fact that the company has had lackluster performance in the stock itself.

Highlights from the ratings report include:

  • The revenue growth came in higher than the industry average of 1.9%. Since the same quarter one year prior, revenues rose by 11.2%. Growth in the company's revenue appears to have helped boost the earnings per share.
  • The company's current return on equity greatly increased when compared to its ROE from the same quarter one year prior. This is a signal of significant strength within the corporation. Compared to other companies in the Pharmaceuticals industry and the overall market, JAZZ PHARMACEUTICALS PLC's return on equity exceeds that of both the industry average and the S&P 500.
  • The gross profit margin for JAZZ PHARMACEUTICALS PLC is currently very high, coming in at 92.42%. It has increased from the same quarter the previous year. Along with this, the net profit margin of 25.80% is above that of the industry average.
  • Net operating cash flow has increased to $175.08 million or 34.98% when compared to the same quarter last year. In addition, JAZZ PHARMACEUTICALS PLC has also vastly surpassed the industry average cash flow growth rate of -57.01%.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.